Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755)
China
· Delayed Price · Currency is CNY 10.90
+0.09 (0.83%)
Sep 9, 2024, 1:35 PM CST
Beijing Aosaikang Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,640 | 1,430 | 1,859 | 3,041 | 3,719 | 4,502 | Upgrade
|
| Other Revenue | 13.77 | 13.77 | 13.61 | 65.22 | 63.37 | 16.33 | Upgrade
|
| Revenue | 1,654 | 1,443 | 1,873 | 3,107 | 3,783 | 4,519 | Upgrade
|
| Revenue Growth (YoY) | 5.10% | -22.92% | -39.72% | -17.87% | -16.29% | 14.92% | Upgrade
|
| Cost of Revenue | 307.93 | 277.51 | 245.7 | 277.05 | 311.44 | 336.21 | Upgrade
|
| Gross Profit | 1,346 | 1,166 | 1,627 | 2,830 | 3,471 | 4,182 | Upgrade
|
| Selling, General & Admin | 1,066 | 973.24 | 1,333 | 2,159 | 2,439 | 2,963 | Upgrade
|
| Research & Development | 307.02 | 472.01 | 588.84 | 324.45 | 255.89 | 310.1 | Upgrade
|
| Other Operating Expenses | 20.42 | 15.67 | 24.89 | 41.19 | 51.99 | 58.82 | Upgrade
|
| Operating Expenses | 1,389 | 1,456 | 1,940 | 2,520 | 2,739 | 3,340 | Upgrade
|
| Operating Income | -42.28 | -290.49 | -313.2 | 309.73 | 732.55 | 842.74 | Upgrade
|
| Interest Expense | -2.81 | -2.81 | -2.76 | -3.99 | -2.96 | -0.05 | Upgrade
|
| Interest & Investment Income | 23.62 | 26.78 | 39.89 | 43.72 | 36.58 | 25.31 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.96 | 0.96 | 0.07 | -0.02 | -0.06 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.56 | -3.19 | -1.89 | -0.08 | -1.77 | -3.18 | Upgrade
|
| EBT Excluding Unusual Items | -17.96 | -268.75 | -277.89 | 349.36 | 764.35 | 864.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.34 | 12.5 | 1.68 | 2.39 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | 0.03 | 0.21 | 0.3 | -0.02 | -2.32 | Upgrade
|
| Asset Writedown | -6.93 | -5.7 | -20.79 | -0.86 | -0.26 | -1.24 | Upgrade
|
| Other Unusual Items | 60.99 | 60.99 | 34.29 | 54.87 | 57.14 | 26.65 | Upgrade
|
| Pretax Income | 50.41 | -200.93 | -262.5 | 406.07 | 821.2 | 887.93 | Upgrade
|
| Income Tax Expense | 12.5 | 6.55 | 3.7 | 25.51 | 95.83 | 108.03 | Upgrade
|
| Earnings From Continuing Operations | 37.92 | -207.48 | -266.21 | 380.56 | 725.37 | 779.9 | Upgrade
|
| Minority Interest in Earnings | 47.6 | 58.95 | 40.38 | -0.66 | -3.74 | 1.06 | Upgrade
|
| Net Income | 85.52 | -148.53 | -225.83 | 379.91 | 721.63 | 780.96 | Upgrade
|
| Net Income to Common | 85.52 | -148.53 | -225.83 | 379.91 | 721.63 | 780.96 | Upgrade
|
| Net Income Growth | - | - | - | -47.35% | -7.60% | 16.55% | Upgrade
|
| Shares Outstanding (Basic) | 935 | 928 | 941 | 927 | 925 | 930 | Upgrade
|
| Shares Outstanding (Diluted) | 935 | 928 | 941 | 927 | 925 | 930 | Upgrade
|
| Shares Change (YoY) | 19.51% | -1.34% | 1.55% | 0.16% | -0.49% | 23.49% | Upgrade
|
| EPS (Basic) | 0.09 | -0.16 | -0.24 | 0.41 | 0.78 | 0.84 | Upgrade
|
| EPS (Diluted) | 0.09 | -0.16 | -0.24 | 0.41 | 0.78 | 0.84 | Upgrade
|
| EPS Growth | - | - | - | -47.44% | -7.14% | -5.62% | Upgrade
|
| Free Cash Flow | 205.26 | -155.89 | -203.27 | 433.95 | 380.7 | 365.6 | Upgrade
|
| Free Cash Flow Per Share | 0.22 | -0.17 | -0.22 | 0.47 | 0.41 | 0.39 | Upgrade
|
| Dividend Per Share | - | - | - | 0.100 | 0.200 | 0.220 | Upgrade
|
| Dividend Growth | - | - | - | -50.00% | -9.09% | 83.33% | Upgrade
|
| Gross Margin | 81.38% | 80.77% | 86.88% | 91.08% | 91.77% | 92.56% | Upgrade
|
| Operating Margin | -2.56% | -20.12% | -16.73% | 9.97% | 19.37% | 18.65% | Upgrade
|
| Profit Margin | 5.17% | -10.29% | -12.06% | 12.23% | 19.08% | 17.28% | Upgrade
|
| Free Cash Flow Margin | 12.41% | -10.80% | -10.86% | 13.97% | 10.06% | 8.09% | Upgrade
|
| EBITDA | 39.06 | -208.88 | -224.03 | 401.33 | 825.17 | 930.72 | Upgrade
|
| EBITDA Margin | 2.36% | -14.47% | -11.96% | 12.92% | 21.81% | 20.60% | Upgrade
|
| D&A For EBITDA | 81.34 | 81.61 | 89.17 | 91.6 | 92.62 | 87.99 | Upgrade
|
| EBIT | -42.28 | -290.49 | -313.2 | 309.73 | 732.55 | 842.74 | Upgrade
|
| EBIT Margin | -2.56% | -20.12% | -16.73% | 9.97% | 19.37% | 18.65% | Upgrade
|
| Effective Tax Rate | 24.79% | - | - | 6.28% | 11.67% | 12.17% | Upgrade
|
| Revenue as Reported | 1,443 | 1,443 | 1,873 | 3,107 | 3,783 | 4,519 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.